PAK2, active
N-terminal 6His and T7, and C-terminal 6His-tagged recombinant, human PAK2, amino acids 3-end.
No items found.
Biological information
Background
p21-activated kinases (PAK) are serine/threonine kinases, which consist of the three highly homologous members PAK1 to -3, regulated by the GTPases Rac1 and Cdc42. PAKs are numerous and include morphogenetic regulation, modulation of signaling cascades leading to transcriptional regulation, and regulation of apoptotic pathways. PAK2 (PAK65) can monophosphorylate the myosin II regulatory light chain and induce retraction of permeabilized endothelial cells. PAK2 also can be activated by caspase-cleavage in addition to p21-binding. PAK2 inhibitors may have therapeutic potential in cancer treatment.
GenBank NM_U24153. The recombinant protein contains the amino acid substitutions L150F, P225T, V383I and (A339 with respect to this accession number. L150F, P225T and (A339 are reported inGenBank NM_U25975. The residue co ordinates in the native sequence have been given.
Target class
Kinase
Family
STE
Accession number
NM_002577.3
Target Name
PAK2, active
Target Alias
PAK2, PAK65, Gamma-PAK, hPAK65, PAKgamma, PAK-2
Origin
Human
Theori. MW
62.8 kDa
Affinity tag
6His
Product specifications
Expression system
Expressed in E. coli
Purity
Refer to CoA for Purity
Purification method
Ni2+/NTA-agarose
Sample Buffer
Specified activity
Refer to CoA
Application
For Research Only
Storage conditions
1 year at -70°C
Usage disclaimer
For Research Only
Chemical data
Background
p21-activated kinases (PAK) are serine/threonine kinases, which consist of the three highly homologous members PAK1 to -3, regulated by the GTPases Rac1 and Cdc42. PAKs are numerous and include morphogenetic regulation, modulation of signaling cascades leading to transcriptional regulation, and regulation of apoptotic pathways. PAK2 (PAK65) can monophosphorylate the myosin II regulatory light chain and induce retraction of permeabilized endothelial cells. PAK2 also can be activated by caspase-cleavage in addition to p21-binding. PAK2 inhibitors may have therapeutic potential in cancer treatment.
GenBank NM_U24153. The recombinant protein contains the amino acid substitutions L150F, P225T, V383I and (A339 with respect to this accession number. L150F, P225T and (A339 are reported inGenBank NM_U25975. The residue co ordinates in the native sequence have been given.
Compound name
Kinase
Catalog number
14-481
Molecular formula
CAS
MW
Ka
Percent composition
Product specifications
Physical state
Purity (HPLC 214nm)
Retention time (RP18 HPLC)
CMC
Exact mass
Stability
For Research Only
Solubility structure
Datasheets
14-481
Datasheet